Friday, April 01, 2022 6:18:54 PM
Can virosome make tumor-specific tumor antigens?
Virosome could make delivery tumor antigens, including Tumor-Specific Antigens (TSA) and Tumor-Associated Antigens (TAA). Virosome compression to the viral vector has much safety and is persuaded to be used.
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: Can virosome make tumor-specific tumor antigens?
What are the advantages of virosome delivery system?
The significant advantage of the virosomes delivery system is adsorbing epitopes of antigens via hydrophobic domains or lipid linker on their surface and inside, furthermore, integrating into phospholipid bilayer.
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: What are the advantages of virosome delivery system?
What triggers antibody-dependent cellular phagocytosis in HIV-1 infection?
Duchemin M., Tudor D., Cottignies-Calamarte A., Bomsel M. Antibody-dependent cellular phagocytosis of HIV-1-infected cells is efficiently triggered by IgA targeting HIV-1 envelope subunit gp41. Front. Immunol. 2020;11[PMC free article][PubMed] [Google Scholar]
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: What triggers antibody-dependent cellular phagocytosis in HIV-1 infection?
What is the efficacy of fusogenic virosome?
The efficacy of fusogenic virosome dramatically depends on the detergents used. After solubilization, it is also challenging to remove low-CMC detergents like octaethylene glycol mono (n-dodecyl) ether (C12E8), Triton X-100, nonidert p-40, and others.
Virosome-based nanovaccines; a promising bioinspiration and biomim…
www.ncbi.nlm.nih.gov/pmc/articles/PMC8049750/
Search for: What is the efficacy of fusogenic virosome?
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM